PMID- 26892043
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20171201
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 374
IP  - 2
DP  - 2016 May 1
TI  - Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of
      epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer
      cells.
PG  - 279-91
LID - 10.1016/j.canlet.2016.02.014 [doi]
LID - S0304-3835(16)30068-4 [pii]
AB  - Recent evidence has suggested a possible role for progesterone receptor (PR) in
      the progression of non-small cell lung cancer (NSCLC). However, little is known
      concerning roles of PR in NSCLC. PR contains a polyproline domain (PPD), which
      directly binds to the SH3 domain of signaling molecules. Because PPD-SH3
      interactions are essential for EGFR signaling, we hypothesized that the presence 
      of PR-PPD interfered with EGFR-mediated signaling and cell proliferation. We
      examined the role of PR-PPD in cell proliferation and signaling by stably
      expressing PR-B, or PR-B with disrupting mutations in the PPD (PR-BDeltaSH3),
      from a tetracycline-regulated promoter in A549 NSCLC cells. PR-B dose-dependently
      inhibited cell growth in the absence of ligand, and progestin (R5020) treatment
      further suppressed the growth. Treatment with RU486 abolished PR-B- and
      R5020-mediated inhibition of cell proliferation. Expression of PR-BDeltaSH3 and
      treatment with R5020 or RU486 had no effect on cell proliferation. Furthermore,
      PR-B expression but not PR-BDeltaSH3 expression reduced EGF-induced A549
      proliferation and activation of ERK1/2, in the absence of ligand. Taken together,
      our data demonstrated the significance of PR extranuclear signaling through PPD
      interactions in EGFR-mediated proliferation and signaling in NSCLC.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Kawprasertsri, Sornsawan
AU  - Kawprasertsri S
AD  - Department of Clinical Chemistry and Graduate Program in Clinical Biochemistry
      and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn
      University, Bangkok 10330, Thailand.
FAU - Pietras, Richard J
AU  - Pietras RJ
AD  - Jonsson Comprehensive Cancer Center and Department of Medicine, Division of
      Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
      90095.
FAU - Marquez-Garban, Diana C
AU  - Marquez-Garban DC
AD  - Jonsson Comprehensive Cancer Center and Department of Medicine, Division of
      Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
      90095.
FAU - Boonyaratanakornkit, Viroj
AU  - Boonyaratanakornkit V
AD  - Department of Clinical Chemistry and Graduate Program in Clinical Biochemistry
      and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn
      University, Bangkok 10330, Thailand; Center of Excellence in Molecular Genetics
      of Cancer and Human Diseases, Chulalongkorn University, Bangkok 10330, Thailand. 
      Electronic address: Viroj.b@chula.ac.th.
LA  - eng
GR  - R21 CA176337/CA/NCI NIH HHS/United States
GR  - U54 CA143930/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160215
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Receptors, Progesterone)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Breast Neoplasms/genetics/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/pathology
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/pathology
MH  - Cell Growth Processes/physiology
MH  - Cell Line, Tumor
MH  - Epidermal Growth Factor/antagonists & inhibitors
MH  - Female
MH  - HEK293 Cells
MH  - Humans
MH  - Lung Neoplasms/genetics/*metabolism/pathology
MH  - Proline-Rich Protein Domains
MH  - Receptor, Epidermal Growth Factor/*antagonists & inhibitors/metabolism
MH  - Receptors, Progesterone/biosynthesis/genetics/*metabolism
MH  - Signal Transduction
PMC - PMC5708136
MID - NIHMS922333
OTO - NOTNLM
OT  - EGFR
OT  - MAPK
OT  - Progesterone receptor
OT  - SH3 domain
OT  - lung cancer
EDAT- 2016/02/20 06:00
MHDA- 2016/08/30 06:00
CRDT- 2016/02/20 06:00
PHST- 2015/12/16 00:00 [received]
PHST- 2016/02/04 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - S0304-3835(16)30068-4 [pii]
AID - 10.1016/j.canlet.2016.02.014 [doi]
PST - ppublish
SO  - Cancer Lett. 2016 May 1;374(2):279-91. doi: 10.1016/j.canlet.2016.02.014. Epub
      2016 Feb 15.